Bayer taps Brunn to lead pharmaceuticals business in Americas region

WHIPPANY, N.J. — Bayer on Tuesday announced that it had named Carsten Brunn as president of its pharmaceuticals division in the Americas. Brunn will oversee the company’s pharmaceutical arm in the United States, Canada, Central and Latin America, reporting to pharmaceutical division president and board of management member Dieter Weinand. 

 

“Carsten is a strategic and highly respected leader in the pharmaceutical industry and I'm delighted to have him lead the company's largest pharmaceutical business worldwide,” said Dieter Weinand. “Carsten's global perspective and proven track record of successful operational execution at the local level will be a critical asset to us as we continue to build on our current momentum in the U.S. and across the Americas region.”

 

Brunn was previously head of Bayer’s pharmaceutical commercial operations in Japan, serving in that role since 2013. He was chairman of the European Federation of Pharmaceutical Industries and Associations Japan. He joined Bayer in 2011 and based in Beijing, China as global head of primary care. Before joining the company, Brunn held leadership roles at companies that include Eli Lilly & Co., Novartis and Bausch & Lomb. 

 

“It has been an incredibly rewarding experience to lead Bayer's pharmaceuticals organization in Japan, and I am honored to have the opportunity to join such an established team here in the United States,” Brunn said. “The U.S. is one of the most important and innovative pharmaceutical markets in the world, where we are in a solid period of consistent growth with strong performance across all our therapeutic areas. I'm thrilled to bring my experiences from other markets to this organization as we continue to build on our strengths and meet the needs of patients.”